GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines division.

AMD’s Q4 2024 earnings report was released at the close of markets today. The tech company reported $7.7 billion in revenue, beating the expectation of $7.5 billion. As for EPS, AMD’s $1.09/share narrowly clears the $1.08/share expectation.

We remain confident in our ability to return to pre-pandemic operating margins in the coming years,” said Pfizer CFO David Denton.

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company’s adjusted EPS of

Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.

The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See why I rate PFE stock as a Hold.

Pfizer reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and sending the stock up about 1% in premarket trading. Pfize

US pharmaceutical giant Pfizer Inc returned to profit in the fourth quarter from a loss in the same period of the previous year, the company reported on Tuesday, while confirming its outlook for the financial year 2025.